The New York Times on Tuesday May 14 contained an op-ed by Angelina Jolie, the actress and director. In it she discloses that she has a family history of breast cancer and that she decided to have a double mastectomy before cancer developed. I have written about this as a patent issue in the past, talking about the Myriad case before the United States Supreme Court, but Ms Jolie’s op-ed puts a personal and familiar face to the problem of genetic issues and patent protection.
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
James Hill, general counsel at Norwich City FC, reveals how he balances fan engagement with brand enforcement, and when he calls on IP firms for advice
In the second of a two-part article, Gabrielle Faure-André and Stéphanie Garçon at Santarelli unpick EPO, UPC and French case law to assess the importance of clinical development timelines in inventive step analyses
Public figures are turning to trademark protection to combat the threat of AI deepfakes and are monetising their brand through licensing deals, a trend that law firms are keen to capitalise on
Tom Melsheimer, part of a nine-partner team to join King & Spalding from Winston & Strawn, says the move reflects Texas’s appeal as a venue for high-stakes patent litigation
Jennifer Che explains how taking on the managing director role at her firm has offered a new perspective, and why Hong Kong is seeing a life sciences boom